ABBOTT LABORATORIES (ABT)

NYSE · SEC-listed source profile

Listing facts

SEC issuer name: ABBOTT LABORATORIES
Ticker: ABT
Exchange: NYSE
Instrument family: Not yet reviewed
SEC issuer CIK: 0000001800
Listing source refreshed: 2026-09-13

Annual financial snapshot

These values are normalized from SEC Companyfacts annual filings. They are issuer-reported accounting facts, not Grizzly Bulls estimates or valuation calculations. Each value retains its filing date, form, SEC concept, and source identity.

Revenue: $44.33B; Period ended 2025-12-31 · filed 2026-02-20 · 10-K; SEC concept: RevenueFromContractWithCustomerExcludingAssessedTax
Net income: $6.52B; Period ended 2025-12-31 · filed 2026-02-20 · 10-K; SEC concept: NetIncomeLoss
Cash: $8.52B; Period ended 2025-12-31 · filed 2026-02-20 · 10-K; SEC concept: CashAndCashEquivalentsAtCarryingValue
Total assets: $86.71B; Period ended 2025-12-31 · filed 2026-02-20 · 10-K; SEC concept: Assets
Stockholders’ equity: $52.13B; Period ended 2025-12-31 · filed 2026-02-20 · 10-K; SEC concept: StockholdersEquity

SEC Companyfacts sourceFetched 2026-09-26

Company Research Map

These reviewed encyclopedia concepts are supported by public-company evidence for this business. Operating-model groups show how the reported concepts fit together without implying that every metric in the broader model is reported by this issuer.

Research coverage

Start with an operating model, then move into the supported concepts and economic bridges below. Coverage counts describe reviewed evidence links for this issuer, not standardized KPI completeness.

Medical Device Portfolio Growth10 of 10 reviewed concepts3 economic bridges

Medical Device Portfolio Growth

10 reviewed concepts

Connects Abbott's comparable Medical Devices growth with franchise-level growth, continuous glucose monitoring, geographic mix and the 2026 Electrophysiology/Structural Heart reclassification.

How these metrics connect

These bridges come from the reviewed operating model. Linked concepts have public-company evidence for this issuer; broader bridge coverage remains explicit when the model contains additional concepts.

Portfolio and geographic growth

2 of 2 reviewed concepts

Total Medical Devices comparable sales growth provides the portfolio baseline, while U.S. versus international comparable growth shows how the aggregate result is distributed geographically.

Cardiovascular franchise mix

6 of 6 reviewed concepts

Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation growth show which cardiovascular and neuromodulation franchises are driving or lagging total Medical Devices growth.

Diabetes and continuous glucose monitoring

2 of 2 reviewed concepts

Diabetes Care growth captures the broader franchise, while CGM comparable growth isolates the continuous-glucose-monitor platform that drives much of the franchise's expansion.